MediWound Earnings Call Transcripts
Fiscal Year 2026
-
NexoBrid is expanding capacity for global burn care markets, while EscharEx is advancing through late-stage trials targeting chronic wounds, with significant clinical advantages over competitors and projected peak U.S. sales of $831 million. Key milestones in 2024 include manufacturing expansion and phase III interim results for EscharEx.
-
A late-stage biologic firm highlighted strong commercial growth for its burn therapy and advanced progress for its chronic wound asset, supported by robust financials and government partnerships. Key catalysts include manufacturing expansion, regulatory milestones, and a pivotal Phase III readout for EscharEx by late 2026.
Fiscal Year 2025
-
2025 saw major clinical and manufacturing milestones, with EscharEx and NexoBrid advancing and revenue guidance reaffirmed for 2026–2028. Despite lower 2025 revenue due to US government delays, the balance sheet was strengthened and long-term growth drivers remain intact.
-
Q3 2025 saw 23% revenue growth, improved margins, and a narrowed net loss, driven by strong EscharEx and NexoBrid progress. Expanded manufacturing and $30M financing support future growth, while regulatory and contract timing remain key uncertainties.
-
Enzymatic wound care products are advancing, with a pivotal phase 3 study for venous leg ulcers and major manufacturing expansion underway. Key catalysts include BARDA contracts, new facilities, and interim clinical results, while strong partnerships and financial stability support growth.
-
Q2 2025 saw strong revenue growth, expanded clinical collaborations, and progress on manufacturing scale-up. NexoBrid U.S. sales rose 52% year-over-year, while S-CoreX trials advanced and new funding was secured. Regulatory approvals and increased capacity are expected in 2026.
-
Q1 2025 saw strong operational execution, with SCRX and NexoBrid programs advancing and global demand outpacing manufacturing. Revenue was $4M, net loss narrowed to $0.7M, and new facilities are on track to support future growth.
-
Validated enzyme-based wound care products are driving strong growth, with Nexobrid generating increasing revenue and EscharEx targeting a much larger market. Strategic partnerships, robust funding, and successful clinical trials position the company for major milestones in 2026 and beyond.
-
Strong demand for enzymatic wound care products is driving expansion, with a new manufacturing facility set to boost capacity sixfold by 2026. EscharEx's phase III trial targets a $2.5B market, with interim results expected mid-2026 and robust prior data supporting its efficacy.
Fiscal Year 2024
-
2024 featured strong clinical and commercial progress, with EscharEx outperforming SANTYL and NexoBrid expanding globally. Revenue grew to $20.2M, but net loss widened due to financial expenses. Manufacturing and regulatory milestones are set to drive further growth in 2025 and beyond.
-
Q3 2024 saw FDA pediatric approval for NexoBrid, strong U.S. demand, and a $25M capital raise. Revenue guidance was revised down due to BARDA, but new manufacturing capacity and EscharEx clinical progress position the company for future growth.
-
Strong demand for NexoBrid and new pediatric approvals are driving growth, but supply is constrained until a new facility is operational. EscharEx is entering a pivotal phase III trial for VLUs, with expansion to DFUs planned and robust funding secured. Key catalysts include U.S. market performance, clinical trial progress, and manufacturing scale-up.
-
Revenue grew year-over-year, driven by NexoBrid's U.S. launch and new contracts, but gross margin declined due to non-recurring costs. Strategic funding and partnerships strengthened the financial position, while clinical programs for EscharEx advanced with significant industry interest.
-
Q1 2024 revenue rose to $5M, driven by NexoBrid, with strong US and international adoption. Manufacturing expansion is on track, EscharEx phase III trial will start in H2 2024, and inclusion in major indexes boosts visibility.